Cargando…
Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Rectal Cancer: Long-Term Results after Protocol-Based Treatment
BACKGROUND: Volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (SIB) is an advanced form of radiotherapy (RT) technology. The purpose of this study was to report long-term treatment outcomes in patients with locally advanced rectal cancer undergoing VMAT-SIB based concurrent...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012974/ https://www.ncbi.nlm.nih.gov/pubmed/35437441 http://dx.doi.org/10.1155/2022/6986267 |
_version_ | 1784687905954856960 |
---|---|
author | Lee, Dong Soo Oh, Seong-Taek Ahn, Chang-Hyeok Lee, Jaeim Lee, Kil-Yong Chae, Hiun Suk Kim, Sung Soo Kim, Sang Woo Seo, Kyung Jin |
author_facet | Lee, Dong Soo Oh, Seong-Taek Ahn, Chang-Hyeok Lee, Jaeim Lee, Kil-Yong Chae, Hiun Suk Kim, Sung Soo Kim, Sang Woo Seo, Kyung Jin |
author_sort | Lee, Dong Soo |
collection | PubMed |
description | BACKGROUND: Volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (SIB) is an advanced form of radiotherapy (RT) technology. The purpose of this study was to report long-term treatment outcomes in patients with locally advanced rectal cancer undergoing VMAT-SIB based concurrent chemoradiotherapy (CRT). METHODS: Between January 2016 and January 2018, a total of 22 patients with operable stage II-III rectal adenocarcinoma were recruited for the pre-designed VMAT-SIB RT protocol. All patients underwent standard diagnostic and staging work-up. The RT target volumes included the following areas: PTV1 = mesorectum that contained gross tumors and enlarged lymph node regions and PTV2 = mesorectum and regional lymphatics from L4-5/S1 to 3-4 cm below the tumor or levator ani muscle, excluding PTV1. The VMAT-SIB dose prescription was as follows: PTV1 = 52.5 Gy/daily 2.1 Gy/25 fractions, PTV2 = 45 Gy/daily 1.8 Gy/25 fractions. RESULTS: The mean age of the study population was 64 (range, 18-84) years, and 15 (68.2%) patients were male. Radical operation (total mesorectal excision) was performed by either low anterior resection, ultralow anterior resection, or abdominal perineal resection. All five (22.7%) of the patients with confirmed increasing serum carcinoembryonic antigen (CEA) level at diagnosis showed normalization of serum CEA level after the planned treatment. Among 20 patients who underwent preoperative CRT and surgery, tumor down staging in T- and N-stages was achieved in 10 patients (50%) and 13 patients (65%), respectively, with 20% of ypT0/Tis. With a median follow-up of 54.2 (range, 22.6-61.1) months, the 5-year disease-free survival, overall survival, and local control rates were 64.6%, 81.8%, and 84.4%, respectively. Five patients developed distant metastasis and one developed local recurrence as a first event. Two cases with anastomosis site leakage, three with adhesive ileus, and two with abscess formation were observed during postoperative periods. CONCLUSIONS: The current VMAT-SIB-based CRT protocol provided acceptable treatment and toxicity outcomes. |
format | Online Article Text |
id | pubmed-9012974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-90129742022-04-17 Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Rectal Cancer: Long-Term Results after Protocol-Based Treatment Lee, Dong Soo Oh, Seong-Taek Ahn, Chang-Hyeok Lee, Jaeim Lee, Kil-Yong Chae, Hiun Suk Kim, Sung Soo Kim, Sang Woo Seo, Kyung Jin J Oncol Research Article BACKGROUND: Volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (SIB) is an advanced form of radiotherapy (RT) technology. The purpose of this study was to report long-term treatment outcomes in patients with locally advanced rectal cancer undergoing VMAT-SIB based concurrent chemoradiotherapy (CRT). METHODS: Between January 2016 and January 2018, a total of 22 patients with operable stage II-III rectal adenocarcinoma were recruited for the pre-designed VMAT-SIB RT protocol. All patients underwent standard diagnostic and staging work-up. The RT target volumes included the following areas: PTV1 = mesorectum that contained gross tumors and enlarged lymph node regions and PTV2 = mesorectum and regional lymphatics from L4-5/S1 to 3-4 cm below the tumor or levator ani muscle, excluding PTV1. The VMAT-SIB dose prescription was as follows: PTV1 = 52.5 Gy/daily 2.1 Gy/25 fractions, PTV2 = 45 Gy/daily 1.8 Gy/25 fractions. RESULTS: The mean age of the study population was 64 (range, 18-84) years, and 15 (68.2%) patients were male. Radical operation (total mesorectal excision) was performed by either low anterior resection, ultralow anterior resection, or abdominal perineal resection. All five (22.7%) of the patients with confirmed increasing serum carcinoembryonic antigen (CEA) level at diagnosis showed normalization of serum CEA level after the planned treatment. Among 20 patients who underwent preoperative CRT and surgery, tumor down staging in T- and N-stages was achieved in 10 patients (50%) and 13 patients (65%), respectively, with 20% of ypT0/Tis. With a median follow-up of 54.2 (range, 22.6-61.1) months, the 5-year disease-free survival, overall survival, and local control rates were 64.6%, 81.8%, and 84.4%, respectively. Five patients developed distant metastasis and one developed local recurrence as a first event. Two cases with anastomosis site leakage, three with adhesive ileus, and two with abscess formation were observed during postoperative periods. CONCLUSIONS: The current VMAT-SIB-based CRT protocol provided acceptable treatment and toxicity outcomes. Hindawi 2022-04-07 /pmc/articles/PMC9012974/ /pubmed/35437441 http://dx.doi.org/10.1155/2022/6986267 Text en Copyright © 2022 Dong Soo Lee et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Lee, Dong Soo Oh, Seong-Taek Ahn, Chang-Hyeok Lee, Jaeim Lee, Kil-Yong Chae, Hiun Suk Kim, Sung Soo Kim, Sang Woo Seo, Kyung Jin Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Rectal Cancer: Long-Term Results after Protocol-Based Treatment |
title | Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Rectal Cancer: Long-Term Results after Protocol-Based Treatment |
title_full | Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Rectal Cancer: Long-Term Results after Protocol-Based Treatment |
title_fullStr | Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Rectal Cancer: Long-Term Results after Protocol-Based Treatment |
title_full_unstemmed | Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Rectal Cancer: Long-Term Results after Protocol-Based Treatment |
title_short | Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Rectal Cancer: Long-Term Results after Protocol-Based Treatment |
title_sort | simultaneous integrated boost volumetric modulated arc therapy for rectal cancer: long-term results after protocol-based treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012974/ https://www.ncbi.nlm.nih.gov/pubmed/35437441 http://dx.doi.org/10.1155/2022/6986267 |
work_keys_str_mv | AT leedongsoo simultaneousintegratedboostvolumetricmodulatedarctherapyforrectalcancerlongtermresultsafterprotocolbasedtreatment AT ohseongtaek simultaneousintegratedboostvolumetricmodulatedarctherapyforrectalcancerlongtermresultsafterprotocolbasedtreatment AT ahnchanghyeok simultaneousintegratedboostvolumetricmodulatedarctherapyforrectalcancerlongtermresultsafterprotocolbasedtreatment AT leejaeim simultaneousintegratedboostvolumetricmodulatedarctherapyforrectalcancerlongtermresultsafterprotocolbasedtreatment AT leekilyong simultaneousintegratedboostvolumetricmodulatedarctherapyforrectalcancerlongtermresultsafterprotocolbasedtreatment AT chaehiunsuk simultaneousintegratedboostvolumetricmodulatedarctherapyforrectalcancerlongtermresultsafterprotocolbasedtreatment AT kimsungsoo simultaneousintegratedboostvolumetricmodulatedarctherapyforrectalcancerlongtermresultsafterprotocolbasedtreatment AT kimsangwoo simultaneousintegratedboostvolumetricmodulatedarctherapyforrectalcancerlongtermresultsafterprotocolbasedtreatment AT seokyungjin simultaneousintegratedboostvolumetricmodulatedarctherapyforrectalcancerlongtermresultsafterprotocolbasedtreatment |